Welcome to our dedicated page for Arvinas SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arvinas, Inc. (NASDAQ: ARVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on targeted protein degradation. Arvinas files current reports on Form 8-K, along with periodic reports such as Forms 10-K and 10-Q, to describe material events, financial results and key developments across its PROTAC pipeline.
In its 8-K filings, Arvinas reports items such as quarterly financial results and corporate updates, presentation of clinical and preclinical data for programs including ARV-102 (a PROTAC LRRK2 degrader), ARV-393 (a BCL6 degrader for non-Hodgkin lymphoma) and ARV-806 (a KRAS G12D degrader for solid tumors), and regulatory milestones for vepdegestrant, its investigational PROTAC estrogen receptor degrader for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. The company also uses 8-Ks to disclose collaboration updates with Pfizer, workforce and cost management actions, and Board and executive changes.
Through this page, users can review how Arvinas describes its PROTAC platform, clinical-stage programs and corporate actions in official SEC documents. Real-time updates from EDGAR allow investors to see new 8-Ks and other filings as they are posted, while AI-powered tools on Stock Titan can help summarize lengthy filings, highlight key sections on topics such as clinical data, regulatory status and capital allocation, and surface patterns across multiple ARVN disclosures.
For those researching ARVN, these filings are a primary source for understanding the status of vepdegestrant’s New Drug Application, the design and progress of trials in oncology and neurodegeneration, and the financial and governance information Arvinas reports to regulators and shareholders.
Arvinas, Inc. shareholder plans a modest Rule 144 stock sale. A holder has filed to sell 5,685 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or around
The filing lists an aggregate market value of
A shareholder of Arvinas, Inc. has filed a notice to sell 4,592 common shares under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of 54607.52. The issuer had 64224294 shares outstanding, and the approximate sale date is 02/13/2026.
The securities were acquired on 02/13/2026 through settlement of vested restricted stock units from Arvinas, Inc., with payment also dated 02/13/2026 and described as not applicable, indicating no separate cash purchase at that time.
Arvinas, Inc. insider plans small stock sale under Rule 144. A person for whose account the shares are held filed to sell 4,403 shares of Arvinas common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market, with an aggregate market value of $52,359.96. These shares were acquired the same day through settlement of vested restricted stock units granted by Arvinas, Inc. The filing notes that shares outstanding were 64,224,294, providing context for the sale’s relative size.
Arvinas, Inc. had an affiliated holder file a Form 144 notice to sell 5,134 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/13/2026 on the NASDAQ market. The shares have an aggregate market value of $61,052.92 based on the figures provided.
The securities to be sold arose from the settlement of vested restricted stock units acquired from Arvinas on 02/13/2026, with payment noted as not applicable. Common shares outstanding were 64,224,294 at the time referenced, providing context for the relative size of this planned sale.
Arvinas, Inc. announced a leadership transition, with longtime executive Randy Teel, Ph.D. becoming president, chief executive officer, principal executive officer, and a board member effective February 12, 2026. Former CEO John Houston, Ph.D. resigned from his officer roles but remains a director and will serve as a consultant.
Teel, who joined Arvinas in 2018 and most recently served as chief business officer, will receive a $680,000 annual base salary and a performance-based bonus target equal to 60% of salary. He is also being granted a stock option for 218,691 shares and a restricted stock unit award covering 147,179 shares, both vesting over four years.
The amended employment agreement provides 12 months of salary and health premium support if Teel is terminated without cause or resigns for good reason outside a change in control, and 18 months of salary, health benefit support, a lump sum equal to 150% of target bonus, and full vesting of unvested equity if this occurs within 12 months after a change in control. Houston’s consulting agreement runs through March 1, 2027 and includes a lump-sum COBRA-related payment of $27,914.40, a $457,000 lump sum tied to the 2025 bonus, potential hourly consulting fees, and continued equity vesting.
Arvinas (ARVN) insider update: Chief Accounting Officer David K. Loomis reported a sale of 230 shares of common stock on 11/07/2025 at $9.89 per share. The filing states the sale was made automatically by the company to cover tax withholding tied to the vesting and settlement of 25% of RSUs granted on December 13, 2022.
Following the transaction, Loomis beneficially owns 31,697 shares directly. This total includes 1,239 shares previously purchased under the company’s 2018 Employee Stock Purchase Plan.
Arvinas (ARVN) reported Q3 2025 results with revenue of $41.9 million versus $102.4 million a year ago and a net loss of $35.1 million versus $49.2 million. Year to date, revenue reached $253.1 million, helped by a change in accounting estimate tied to the Pfizer collaboration that increased revenue by $150.2 million and reduced net loss accordingly. The company also recognized $20.0 million upon a Novartis development milestone for luxdegalutamide (ARV-766).
Operating discipline was evident: research and development expense fell to $64.7 million from $86.9 million, and general and administrative expense declined to $21.0 million from $75.8 million. Cash, cash equivalents and marketable securities totaled $787.6 million as of September 30, 2025. Operating cash outflow was $243.4 million for the first nine months.
Arvinas announced a $100.0 million share repurchase program and bought 2,560,030 shares for $20.2 million in Q3, leaving $79.8 million authorized. With Pfizer, the company agreed to jointly select a third party for commercialization and potential further development of vepdegestrant, and implemented workforce reductions to streamline operations.
Arvinas, Inc. reported that it announced its financial results for the quarter ended September 30, 2025 and provided a corporate update. The company released these details in a press release dated November 5, 2025, which is furnished as Exhibit 99.1 to this current report. The information in this earnings-related section is furnished rather than filed, meaning it is not subject to certain securities law liabilities unless specifically incorporated into other documents.
Arvinas (ARVN) reported new preclinical results for ARV-806, a PROTAC degrader targeting the KRAS G12D mutation, presented at the 2025 AACR‑NCI‑EORTC “Triple Meeting.” The program aims at a common KRAS mutation found in pancreatic, colorectal, and non‑small cell lung cancers.
In cell studies, ARV‑806 degraded KRAS G12D with picomolar potency and spared wild‑type and other RAS isoforms. Compared with clinical‑stage KRAS G12D ON and OFF inhibitors and another clinical‑stage G12D degrader, it showed >25‑fold greater anti‑proliferative potency, >40‑fold higher degradation potency (vs the comparable degrader), and required >10‑fold lower concentrations to induce pro‑apoptotic BIM. In a colorectal tumor xenograft model, a single IV dose achieved >90% KRAS G12D degradation for seven days, with parallel c‑MYC suppression and BIM induction for ≥5 days. Tumor models showed ≥30% volume reductions across pancreatic and colorectal CDX and a lung PDX model. The company is evaluating ARV‑806 in a Phase 1 trial in KRAS G12D‑mutated advanced solid tumors.
Arvinas (ARVN) reported new patient-reported outcomes from the Phase 3 VERITAC-2 trial of vepdegestrant, presented at ESMO 2025. The company said vepdegestrant showed a reduced risk of deterioration versus fulvestrant in patients with ESR1‑mutated, ER+/HER2‑ advanced or metastatic breast cancer previously treated with endocrine therapy, with statistically significant advantages in several PRO domains including overall health status, pain severity, and role, cognitive, emotional, and social functioning.
Vepdegestrant is an investigational PROTAC estrogen receptor degrader being developed with Pfizer as a potential monotherapy for ESR1‑mutated ER+/HER2‑ disease. Arvinas also highlighted Phase 2 TACTIVE‑N results in a neoadjuvant setting for ER+/HER2‑ localized breast cancer in postmenopausal women, where vepdegestrant demonstrated biological and clinical activity. The company furnished a press release as Exhibit 99.1 and noted the information is provided under Regulation FD and Other Events.